Home > News > Altair Nanotechnologies Licenses RenaZorb(TM)
January 31st, 2005
Altair Nanotechnologies Licenses RenaZorb(TM)
Abstract:
Altair Nanotechnologies announced today that a licensing agreement has been signed with California-based Spectrum Pharmaceuticals, giving Spectrum the exclusive worldwide rights for human therapeutic and diagnostic applications to develop, market and sell its RenaZorb™ product line. Altair's RenaZorb™ products, which target an emerging billion-dollar-plus market, are for phosphate control in patients with Chronic Kidney Disease (CKD) and hyperphosphatemia, high phosphate levels in blood, associated with End Stage Renal Disease (ESRD). These products are non-aluminum-, non-calcium-based phosphate binders, which utilize Altair's proprietary lanthanum nanomaterial technology.
Source:
marketwire
Bookmark:
| Related Links |
| Related News Press |
Nanomedicine
Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018
Observing biological nanotransporters: Chemistry April 19th, 2018
Nanobiotix Shows NBTXR3 Nanoparticles Can Stoke Anti-Tumor Immune Response April 17th, 2018
Announcements
Getting electrons to move in a semiconductor: Gallium oxide shows high electron mobility, making it promising for better and cheaper devices April 24th, 2018
Organic solar cells reach record efficiency, benchmark for commercialization April 23rd, 2018
Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018
Patents/IP/Tech Transfer/Licensing
NTU scientists create customizable, fabric-like power source for wearable electronics January 30th, 2018
A new product to help combat mouldy walls, thanks to technology developed at the ICN2 December 14th, 2017
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||